Chemotherapeutic Drugs Inhibit Ribosome Biogenesis at Various Levels
Open Access
- 1 April 2010
- journal article
- Published by Elsevier BV
- Vol. 285 (16), 12416-12425
- https://doi.org/10.1074/jbc.m109.074211
Abstract
No abstract availableThis publication has 38 references indexed in Scilit:
- Defects in 18 S or 28 S rRNA Processing Activate the p53 PathwayPublished by Elsevier BV ,2010
- The Chemical Genomic Portrait of Yeast: Uncovering a Phenotype for All GenesScience, 2008
- Depletion of the Yeast Nuclear Exosome Subunit Rrp6 Results in Accumulation of Polyadenylated RNAs in a Discrete Domain within the NucleolusMolecular and Cellular Biology, 2007
- Interdependence of Pes1, Bop1, and WDR12 Controls Nucleolar Localization and Assembly of the PeBoW Complex Required for Maturation of the 60S Ribosomal SubunitMolecular and Cellular Biology, 2007
- Cancer-Associated Mutations in the MDM2 Zinc Finger Domain Disrupt Ribosomal Protein Interaction and Attenuate MDM2-Induced p53 DegradationMolecular and Cellular Biology, 2007
- Incorporation of 5-fluorouracil into U2 snRNA blocks pseudouridylation and pre-mRNA splicing in vivoNucleic Acids Research, 2006
- Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemiaBlood, 2006
- Dominant-negative Pes1 mutants inhibit ribosomal RNA processing and cell proliferation via incorporation into the PeBoW-complexNucleic Acids Research, 2006
- Disruption of the nucleolus mediates stabilization of p53 in response to DNA damage and other stressesThe EMBO Journal, 2003
- Disruption of p53 in human cancer cells alters the responses to therapeutic agentsJCI Insight, 1999